Clinical Trials
25 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Ohio State University Comprehensive Cancer Center
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
Xiangya Hospital of Central South University
EVIDENT
Oslo University Hospital
FOLFOX-D
University of Florida
Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Massachusetts General Hospital
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
Swiss Cancer Institute
Trial of Dasatinib in Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Translational Oncology Research International
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
National Cancer Institute (NCI)
A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
Peking University Cancer Hospital & Institute
LAPC
Otsuka Pharmaceutical Development & Commercialization, Inc.
XAD
Duke University
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Centro Nacional de Investigaciones Oncologicas CARLOS III
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
City of Hope Medical Center
Gem/Dsat
Duke University
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
National Cancer Institute (NCI)
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
National Cancer Institute (NCI)